Articles by Louis Garguilo

31. Amgen Looks To Air And Auto For Advice 4/11/2016

    There are roughly 38,000 components that go into building a commercial airplane; in the automotive industry, it’s about 13,000  to build a car. “That requires just a little bit of coordination,” says Rodney MacLea of Amgen. If companies in those industries effectively manage much larger supply chains, why can’t pharma improve its performance? MacLea and Amgen set out to find out.

32. The New Leadership Marketing 3/31/2016

    Marketing today centers on the demonstration of active leadership and its promotion. Executive Editor Louis Garguilo describes this as “leadership marketing,” and says it's a step beyond what has become a stagnant “thought leadership.” He also puts value in a name, and thinks large conferences don’t fit this new age.

33. Genentech Speaks The Language Of CMOs 3/28/2016

    Todd Mabe, head of External Quality, Biologics Drug Substance for Genentech, knows his company has an inherent advantage when contracting for biologics production capacity. “It’s fair to say we’re a popular customer target,” he explains. But that doesn’t make the selection process a walk in the park. 

34. Biogen's Outsourcing Trifold For Joint Value Creation 3/22/2016

    Purposeful segmentation, descriptive scorecards and matrixes, and CMO governance, form a trifold of strategic relationship management for Biogen’s supply chain, says Thomas Holmes, senior director for Global External Manufacturing.  

35. In Outsourcing, Genzyme Sees An Advantage 3/16/2016

    Regarding the outsourcing of biologics manufacturing, Piet Houwen of Sanofi says, “Starting from today, where I’d say the market relationship is sixty percent driven by the sellers, I believe we’ll see a change to a move in the direction of the sponsors.”

36. Is The Virtual Biotech Model In Jeopardy? 3/10/2016

    It appeared we were coasting uninterrupted to a global outsourcing industry fully able to support a wide variety of virtual business models and strategies. But conversations with executives at established biotechs reveal an unfolding reality.

37. At Biogen, Three Keys To Outsourcing 3/2/2016

    Thomas Holmes, senior director for Global External Manufacturing, Biogen, says: (a) cost is not the strategic driver in CMO selection; (b) “dual sourcing” is revenue independent; and (c) the time from drug approval to market launch is all of 48 to 72 hours. 

38. The Enlightened Battles Of Biopharma Outsourcing 3/1/2016

    In drug development, the threat level is always immanent. Too often there’s no alternative to preparing a detailed map of a landscape that may not exist. “Outsourcing” is the inadequate label we’ve affixed to a potent weapon to more effectively wage winning campaigns. 

39. Biopharma Outsourcing Past Is Prologue 2/24/2016

    It seems the more things change, the more these three components – biopharma entrepreneurs, financial backers, and outsourcing service providers – need to work together. The past helps us see this future more clearly. 

40. Biopharma Climbs The Serialization Mountain 2/11/2016

    The data associated with drug-product serialization will be Everest-like; accessing it may pose every bit the security risk. The difference is millions of people may be trying to access the summit … every day. What’s clear today is that a national program for drug serialization looms large on the horizon, and rises, if you will, high into the data clouds.